To provide a method for efficiently and effectively discriminating the presence or absence of the efficacy of an infliximab administering on a gene level by analyzing the gene expression profile of a blood sample.
The method for discriminating the efficacy of the infliximab medicinal effect in a patient with rheumatoid arthritis using one or more indicators selected from a plurality of indicators includes: a process for measuring the expression level of one or more genes selected from a specific group in blood of the patient with rheumatoid arthritis; a process for analyzing the measured expression level, using the gene expression profile prepared beforehand; and a process for discriminating the efficacy of infliximab medicinal effect in the patient with rheumatoid arthritis based on the analysis result.
MATOBA AKIRA
NAKAMURA SEIJI
SHIMODA MASABUMI
MATSUBARA KENICHI
TAKEUCHI TSUTOMU
OKAYAMA TOSHIJI
TAMURA TAKURO
JPN6014047257; 肺癌 Ｖｏｌ．４６， Ｎｏ．３, 2006, ｐｐ．２４５-２５１
Yoshiyuki Sasaki
Kazuya Sekiguchi
Next Patent: HBM VARIANTS THAT MODULATE BONE MASS AND LIPID LEVELS